Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors

  • Technology appraisal guidance
  • TA407
  • Published: 

History

Documents created during the development process.

Final appraisal determination

Invitation to participate

Draft scope for consultation (pre-referral) - January 2015

Provisional matrix (pre-referral) - January 2015